Viking Therapeutics (VKTX) – VK2735 subQ Moving into Phase III & Oral Phase II by Year End As VK2735 Continues Emergence as Best-in-Class GLP

BIOINVEST BREAKING NEWS – Viking (VKTX) held an excellent Q2:24 call with important positive clinical and regulatory updates for both VK2735 subQ and oral. BUY. (…more)

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.